These results suggest that 1-PPA treatment can protect from tissue damage and multi-organ failure induced by LPS in experimental sepsis, providing evidence that PAR2 inhibition is a crucial event in preventing the activation of pathways leading to cytokine release, hypercoagulable state, and vasodilation, which are the hallmarks of septic shock. This evidence concerns the gene F2RL1 and Sepsis.